NEXT Oncology Opens Newest Phase 1 Clinical Trial Center in Houston, Texas

With continued global expansion plans, NEXT Oncology is one of the largest Phase 1 Cancer Trial organizations in the world. (SAN ANTONIO, TX) March 25, 2025 ––NEXT Oncology has opened its seventh cancer care center in Houston, Texas as part of the company’s global growth initiative.  NEXT – Houston, which will be led by Dr. Peter DeMaria and Dr. Jennifer …

NEXT Oncology Moves Cancer Research Forward

NEXT Oncology, a Phase 1 Clinical Trial organization with six locations around the world, played a significant role in moving cancer research forward at the recent American Society of Clinical Oncology (ASCO) meeting in Chicago. Clinical investigators from NEXT locations around the world presented 25 abstracts, posters and presentations on the status of ongoing Phase 1 clinical trials at NEXT …

Announcing the 2024 Health Care Heroes

“We are so proud of our founder and CEO, Dr. Anthony Tolcher” for being named one of San Antonio’s Health Care Heroes by the San Antonio Business Journal. We will celebrate his achievements on May 22, 2024. Read more here.

Dr. Sen

NEXT Oncology is the perfect place to compassionately improve outcomes for patients with cancer, now and in the future.

“Cancer has no geographic boundaries,” said Dr. Tolcher, CEO and founder of NEXT Oncology. “One of the continuing challenges has been that cancer research has been conducted in silos. Our goal has always been to break down those barriers and bring potentially life-saving therapies to people in other cities within Texas, while at the same time expediting the development of new …

ADCs in Breast Oncology: Present & Future

Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks.  Educational Symposium on ADCs @ December 2022 SABCS. Bioengineering & Mechanism of Action of Antibody Drug Conjugates (ADC) Presentation from Puja Sapra, PhD with SVP Biologics Engineering and …

Pregnancy Outcome & Safety of Interrupting Therapy for Women with Endocrine ResponsIVE Breast Cancer.

Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks.  POSITIVE TRIAL Pregnancy Outcome & Safety of Interrupting Therapy for Women with Endocrine ResponsIVE Breast Cancer. (Initial Results from the POSITIVE Trial presented by Ann Partridge Harvard Medical …

Pregnancy and Breast Cancer

Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks. Recently, I attended two conferences about breast cancer, and both covered the special issue related to Pregnancy and Breast cancer. I think we are covering this issue more …

Phase I Clinical Trial Enrollment Q&A with NEXT Oncology Physicians

Cancer patients and their caregivers often have questions when exploring treatment options, especially when it comes to early-stage clinical trials. The physicians and clinical investigators at NEXT Oncology have pulled together a list of frequently asked questions. In this blog, they answer the questions in a succinct manner, but encourage patients to have more in-depth conversations with their physicians when …